UK CMO appoints new director
Sterile manufacturing specialist Symbiosis Pharmaceutical Services has appointed Joanne Anderson as its new Business Development Director to help drive its commercial growth.
Symbiosis Pharmaceutical Service has promoted Mrs Anderson to the role following three successful years with the Scotland-based pharmaceutical contract manufacturing organisation (CMO) and will join the management team.
Reporting to the CEO, her responsibilities will include the strategic and operational management of all sales and marketing activities for Symbiosis globally.
A qualified analytical chemist with an MBA, Mrs Anderson has worked in the biopharmaceutical outsourcing sector for almost 15 years and has spent the last 8 years specialising in the field of sterile injectable products for clinical trials and low volume commercial supply.
Colin MacKay, CEO at Symbiosis Pharmaceutical Services, said: “Joanne has made an increasingly valuable contribution to the commercial team over the last few years in terms of generating market awareness of the world-class services offered by Symbiosis and her highly professional approach to successfully achieving significant year-on-year sales revenue growth.
“As we look to further expand the business, it’s essential for us to have a management team comprising knowledgeable, high-performing and well-respected industry professionals in key senior roles. Our decision to appoint Joanne as our Business Development Director aligns perfectly with that.”
Symbiosis recently announced plans to expand its sterile filling facility following increased demand for its small-scale sterile manufacturing services and to ensure continued compliance with the latest interpretation of the guidelines by the MHRA.
Mrs Anderson said: “We are at a very important stage of the company’s development so I am delighted and honoured to have been promoted into this new role to drive the commercial development of the company and take Symbiosis to the next level.
“Recent investments into our facility enable us to aseptically manufacture and provide lyophilization services at both the clinical stage and for clients with niche licensed products.
“My job is to ensure potential and existing clients know that we are not only a safe pair of hands from a technical and quality perspective, but that we are time focussed in our approach to the cGMP manufacture of drug products to ensure tight timelines are met.
“It’s also important that our customers understand that our strength comes from our focus on exceeding client expectations and delivering a world-class service," added Mrs Anderson.
Symbiosis specialises in the sterile fill/finish of biologic and small molecule products into vials, which are either liquid or lyophilised formulations. The fast-growing CMO’s capabilities include the ability to handle and fill antibodies, proteins, peptides, nucleic acids, cytotoxic, cytostatic and highly potent APIs including ADCs along with conventional small molecules.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance